Journal
RADIATION ONCOLOGY
Volume 11, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13014-016-0646-2
Keywords
PSMA-PET; Prostate cancer; Radiation therapy; Radiation oncology; Treatment planning
Funding
- Deutsche Forschungsgemeinschaft, Bonn, Germany [SFB 824 (DFG Sonderforschungsbereich 824)]
Ask authors/readers for more resources
Background: Prostate cancer (PC) is one of the most commonly treated cancer entities with radiation therapy (RT). Risk group-adapted treatment and avoidance of unnecessary toxicities relies primarily on accurate tumor staging. Thus, the introduction of prostate-specific membrane antigen (PSMA) in diagnosis and treatment of PC is a highly interesting development in radiation oncology of urologic tumors. The present work is to evaluate the integration of Ga-68-PSMA-PET imaging into standard radiation planning of primary definitive treatment of PC and to determine the impact of PSMA imaging on tumor staging. Methods: The data of 15 patients treated for PC between August 2013 and April 2015 were evaluated. Treatment planning included Ga-68-PSMA-PET imaging. We analyzed whether the use of PSMA-imaging led to a change of the TNM stage and if it influenced the RT treatment approach or the target volume, due to changes in the gross tumor volume (GTV) or clinical target volume (CTV), in the final treatment plan. Results: In 53.3 % of the analyzed patients a change occurred in the TNM stage based on Ga-68-PSMA-PET examination. The RT concept changed in 33.3 % of all patients, leading to relevant changes in the planning target volume. Among these, an additional irradiation of the pelvic lymph drainage due to tracer uptake in lymph nodes was performed in 25 %. Furthermore, boost volumes of PET-positive lymph nodes were added in 80 % of these cases. A down staging due to the Ga-68-PSMA-PET examination occurred in 13.3 % of all cases. Conclusions: The integration of Ga-68-PSMA-PET-imaging into the RT treatment planning process can be useful for detailed target volume planning. The performance of a Ga-68-PSMA-PET frequently leads to changes in the TNM stage, altering the RT treatment regimen and the target volume. A prospective trial is underway to evaluate the impact of Ga-68-PSMA-PET based treatment planning on outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available